NeRRe Therapeutics
VerifiedDevelops clinical and pre-clinical neurokinin receptor antagonists
Launch date
Employees
Ownership
Firm valuation
$152m (Dealroom.co estimates Jul 2021.)
Stevenage England (HQ)
Financials
Edit| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E |
|---|---|---|---|---|---|---|---|
| EBITDA | (2m) | (9m) | (9m) | (10m) | (6m) | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| $18.4m | Series A | ||
| £23m | Series B | ||
| £20m Valuation: £115m | Series B | ||
| Total Funding | $75.2m | ||
Recent News about NeRRe Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.